S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:INMB

INmune Bio (INMB) Stock Price, News & Analysis

$11.75
+0.12 (+1.03%)
(As of 03/28/2024 ET)
Today's Range
$11.28
$12.05
50-Day Range
$10.53
$14.01
52-Week Range
$5.87
$14.74
Volume
96,381 shs
Average Volume
64,016 shs
Market Capitalization
$211.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

INmune Bio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
36.2% Upside
$16.00 Price Target
Short Interest
Bearish
12.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of INmune Bio in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.84 out of 5 stars

Medical Sector

851st out of 938 stocks

Biotechnology Industry

39th out of 47 stocks

INMB stock logo

About INmune Bio Stock (NASDAQ:INMB)

INmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

INMB Stock Price History

INMB Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
INmune Bio (NASDAQ:INMB) Stock Price Down 4%
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
INMB Jun 2024 25.000 call
INMB Mar 2024 20.000 call
INMB Mar 2024 12.500 put
INMB Feb 2024 15.000 put
INmune Bio Inc (INMB)
INmune Bio: FDA Removes Clinical Hold For Alzheimer's Disease Program
See More Headlines
Receive INMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
3/28/2024
Next Earnings (Confirmed)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:INMB
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.00
High Stock Price Target
$16.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+36.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-27,300,000.00
Net Margins
-12,246.88%
Pretax Margin
-12,246.88%

Debt

Sales & Book Value

Annual Sales
$370,000.00
Book Value
$3.35 per share

Miscellaneous

Free Float
11,516,000
Market Cap
$211.74 million
Optionable
Optionable
Beta
1.99
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

INMB Stock Analysis - Frequently Asked Questions

Should I buy or sell INmune Bio stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INMB shares.
View INMB analyst ratings
or view top-rated stocks.

What is INmune Bio's stock price target for 2024?

1 Wall Street analysts have issued 1-year price objectives for INmune Bio's stock. Their INMB share price targets range from $16.00 to $16.00. On average, they anticipate the company's share price to reach $16.00 in the next year. This suggests a possible upside of 36.2% from the stock's current price.
View analysts price targets for INMB
or view top-rated stocks among Wall Street analysts.

How have INMB shares performed in 2024?

INmune Bio's stock was trading at $11.26 at the beginning of 2024. Since then, INMB stock has increased by 4.4% and is now trading at $11.75.
View the best growth stocks for 2024 here
.

How were INmune Bio's earnings last quarter?

INmune Bio, Inc. (NASDAQ:INMB) posted its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.12. The firm earned $0.01 million during the quarter. INmune Bio had a negative trailing twelve-month return on equity of 52.26% and a negative net margin of 12,246.88%. During the same period in the previous year, the firm posted ($0.36) earnings per share.

What other stocks do shareholders of INmune Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other INmune Bio investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Cidara Therapeutics (CDTX), Gilead Sciences (GILD), Cisco Systems (CSCO), Vaxart (VXRT), Micron Technology (MU), Novavax (NVAX) and SCYNEXIS (SCYX).

Who are INmune Bio's major shareholders?

INmune Bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.00%), Vanguard Group Inc. (3.00%), Janney Montgomery Scott LLC (0.91%), Royal Bank of Canada (0.32%), UBS Group AG (0.24%) and Fermata Advisors LLC (0.16%). Insiders that own company stock include David J Moss, Mark William Lowdell, Raymond Joseph Tesi, Scott Juda and Timothy J Schroeder.
View institutional ownership trends
.

How do I buy shares of INmune Bio?

Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INMB) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners